Cargando…

Survival analysis of women breast cancer patients in Northwest Amhara, Ethiopia

INTRODUCTION: Breast cancer, the most common cause of cancer death and the most frequently diagnosed cancer among women worldwide, ranks as the second cause of death next to lung cancer. Thus, the main objective was to assess the factors that affect the survival time of breast cancer patients using...

Descripción completa

Detalles Bibliográficos
Autores principales: Feleke, Bereket, Tesfaw, Lijalem Melie, Mitku, Aweke A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808778/
https://www.ncbi.nlm.nih.gov/pubmed/36605442
http://dx.doi.org/10.3389/fonc.2022.1041245
_version_ 1784863005310189568
author Feleke, Bereket
Tesfaw, Lijalem Melie
Mitku, Aweke A.
author_facet Feleke, Bereket
Tesfaw, Lijalem Melie
Mitku, Aweke A.
author_sort Feleke, Bereket
collection PubMed
description INTRODUCTION: Breast cancer, the most common cause of cancer death and the most frequently diagnosed cancer among women worldwide, ranks as the second cause of death next to lung cancer. Thus, the main objective was to assess the factors that affect the survival time of breast cancer patients using the shared frailty model. METHODS: A retrospective study design was used to collect relevant data on the survival time of breast cancer patients from the medical charts of 322 breast cancer patients under follow-up at the Felege Hiwot Comprehensive Specialized Hospital (FHCSH). The data were explored using the Cox proportional hazard model, the accelerated failure time model, and shared frailty models. The model comparison was done using AIC and BIC. As a result, the Weibull gamma shared frailty model had a minimum AIC and BIC value. RESULT: From a total of 322 patients, about 95 (29.5%) died and 227 (70.5%) were censored. The overall mean and median estimated survival times of breast cancer patients under study were 43.7 and 45 months, respectively. The unobserved heterogeneity in the population of clusters (residence) as estimated by the Weibull-gamma shared frailty model was 0.002 (p-value = 0.000), indicating the presence of residential variation in the survival time of breast cancer patients. The estimated hazard rate of patients who had not had recurrent breast cancer was 0.724 (95% CI: 0.571, 0.917) times the estimated hazard rate of patients who had had recurrent breast cancer. CONCLUSION: The prevalence of breast cancer was considerably high. Under this investigation, older patients, patients in stages III and IV, anemic and diabetes patients, patients who took only chemotherapy treatment, metastasized patients, patients with an AB blood type, patients with a positive breast cancer family history, and patients whose cancer was recurrent had high death rates. Patient characteristics such as age, stage, complications, treatment, metastasis, blood type, family history, and recurrence were significant factors associated with the survival time of women with breast cancer.
format Online
Article
Text
id pubmed-9808778
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98087782023-01-04 Survival analysis of women breast cancer patients in Northwest Amhara, Ethiopia Feleke, Bereket Tesfaw, Lijalem Melie Mitku, Aweke A. Front Oncol Oncology INTRODUCTION: Breast cancer, the most common cause of cancer death and the most frequently diagnosed cancer among women worldwide, ranks as the second cause of death next to lung cancer. Thus, the main objective was to assess the factors that affect the survival time of breast cancer patients using the shared frailty model. METHODS: A retrospective study design was used to collect relevant data on the survival time of breast cancer patients from the medical charts of 322 breast cancer patients under follow-up at the Felege Hiwot Comprehensive Specialized Hospital (FHCSH). The data were explored using the Cox proportional hazard model, the accelerated failure time model, and shared frailty models. The model comparison was done using AIC and BIC. As a result, the Weibull gamma shared frailty model had a minimum AIC and BIC value. RESULT: From a total of 322 patients, about 95 (29.5%) died and 227 (70.5%) were censored. The overall mean and median estimated survival times of breast cancer patients under study were 43.7 and 45 months, respectively. The unobserved heterogeneity in the population of clusters (residence) as estimated by the Weibull-gamma shared frailty model was 0.002 (p-value = 0.000), indicating the presence of residential variation in the survival time of breast cancer patients. The estimated hazard rate of patients who had not had recurrent breast cancer was 0.724 (95% CI: 0.571, 0.917) times the estimated hazard rate of patients who had had recurrent breast cancer. CONCLUSION: The prevalence of breast cancer was considerably high. Under this investigation, older patients, patients in stages III and IV, anemic and diabetes patients, patients who took only chemotherapy treatment, metastasized patients, patients with an AB blood type, patients with a positive breast cancer family history, and patients whose cancer was recurrent had high death rates. Patient characteristics such as age, stage, complications, treatment, metastasis, blood type, family history, and recurrence were significant factors associated with the survival time of women with breast cancer. Frontiers Media S.A. 2022-12-19 /pmc/articles/PMC9808778/ /pubmed/36605442 http://dx.doi.org/10.3389/fonc.2022.1041245 Text en Copyright © 2022 Feleke, Tesfaw and Mitku https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Feleke, Bereket
Tesfaw, Lijalem Melie
Mitku, Aweke A.
Survival analysis of women breast cancer patients in Northwest Amhara, Ethiopia
title Survival analysis of women breast cancer patients in Northwest Amhara, Ethiopia
title_full Survival analysis of women breast cancer patients in Northwest Amhara, Ethiopia
title_fullStr Survival analysis of women breast cancer patients in Northwest Amhara, Ethiopia
title_full_unstemmed Survival analysis of women breast cancer patients in Northwest Amhara, Ethiopia
title_short Survival analysis of women breast cancer patients in Northwest Amhara, Ethiopia
title_sort survival analysis of women breast cancer patients in northwest amhara, ethiopia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808778/
https://www.ncbi.nlm.nih.gov/pubmed/36605442
http://dx.doi.org/10.3389/fonc.2022.1041245
work_keys_str_mv AT felekebereket survivalanalysisofwomenbreastcancerpatientsinnorthwestamharaethiopia
AT tesfawlijalemmelie survivalanalysisofwomenbreastcancerpatientsinnorthwestamharaethiopia
AT mitkuawekea survivalanalysisofwomenbreastcancerpatientsinnorthwestamharaethiopia